Gilead Gets HIV Generic Drugs Barred From Market Until 2036

Gilead Sciences Inc. said Monday it is keeping generic forms of its HIV treatment Biktarvy off of the market until 2036 following a series of settlements with competitors....

Already a subscriber? Click here to view full article